Aarti Pharmalabs Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 10 May 2025.

Powered by Capital Market - Live News

Aarti Pharmalabs announced that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger.

The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs' dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy efficient initiatives across its operations, and active engagement with its value chain partners.

Powered by Capital Market - Live News

Revenue from operations grew 19.9% to Rs 537.78 crore in the quarter ended 31 December 2024.

Profit before tax was at Rs 100.63 crore in the third quarter of FY25, up 36.3% from Rs 73.82 crore posted in the same period a year ago.

Total expenses increased 17.5% to Rs 442.18 crore in Q3 FY25, compared to Rs 376.26 crore reported in Q3 FY24. The cost of material consumed stood at Rs 261.19 crore (up 21.5% YoY), employee benefit expenses was at Rs 41.63 crore (up 15.1% YoY) and finance costs stood at Rs 9.97 crore (up 122.5% YoY) during the period under review.

On nine-month basis, the company's consolidated net profit jumped 21.4% to Rs 184.06 crore in 9M FY25, compared to Rs 151.65 crore in 9M FY24. Revenue from operations rose 15.2% YoY to Rs 1,551.30 crore in 9M FY25.

The company's board has declared an interim dividend of Rs 2.5 per equity share for the financial year 2024-25. The record date for the payment of the interim dividend has been set for Friday, 14 February 2025.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India.

Powered by Capital Market - Live News

Aarti Pharmalabs announced that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger.

The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs' dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy efficient initiatives across its operations, and active engagement with its value chain partners.

Powered by Capital Market - Live News

Revenue from operations grew 19.9% to Rs 537.78 crore in the quarter ended 31 December 2024.

Profit before tax was at Rs 100.63 crore in the third quarter of FY25, up 36.3% from Rs 73.82 crore posted in the same period a year ago.

Total expenses increased 17.5% to Rs 442.18 crore in Q3 FY25, compared to Rs 376.26 crore reported in Q3 FY24. The cost of material consumed stood at Rs 261.19 crore (up 21.5% YoY), employee benefit expenses was at Rs 41.63 crore (up 15.1% YoY) and finance costs stood at Rs 9.97 crore (up 122.5% YoY) during the period under review.

On nine-month basis, the company's consolidated net profit jumped 21.4% to Rs 184.06 crore in 9M FY25, compared to Rs 151.65 crore in 9M FY24. Revenue from operations rose 15.2% YoY to Rs 1,551.30 crore in 9M FY25.

The company's board has declared an interim dividend of Rs 2.5 per equity share for the financial year 2024-25. The record date for the payment of the interim dividend has been set for Friday, 14 February 2025.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India.

Powered by Capital Market - Live News

Net profit of Aarti Pharmalabs rose 40.24% to Rs 73.99 crore in the quarter ended December 2024 as against Rs 52.76 crore during the previous quarter ended December 2023. Sales rose 19.86% to Rs 537.78 crore in the quarter ended December 2024 as against Rs 448.69 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 10 May 2025.

Powered by Capital Market - Live News

Aarti Pharmalabs announced that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger.

The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs' dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy efficient initiatives across its operations, and active engagement with its value chain partners.

Powered by Capital Market - Live News

Revenue from operations grew 19.9% to Rs 537.78 crore in the quarter ended 31 December 2024.

Profit before tax was at Rs 100.63 crore in the third quarter of FY25, up 36.3% from Rs 73.82 crore posted in the same period a year ago.

Total expenses increased 17.5% to Rs 442.18 crore in Q3 FY25, compared to Rs 376.26 crore reported in Q3 FY24. The cost of material consumed stood at Rs 261.19 crore (up 21.5% YoY), employee benefit expenses was at Rs 41.63 crore (up 15.1% YoY) and finance costs stood at Rs 9.97 crore (up 122.5% YoY) during the period under review.

On nine-month basis, the company's consolidated net profit jumped 21.4% to Rs 184.06 crore in 9M FY25, compared to Rs 151.65 crore in 9M FY24. Revenue from operations rose 15.2% YoY to Rs 1,551.30 crore in 9M FY25.

The company's board has declared an interim dividend of Rs 2.5 per equity share for the financial year 2024-25. The record date for the payment of the interim dividend has been set for Friday, 14 February 2025.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India.

Powered by Capital Market - Live News

Aarti Pharmalabs announced that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger.

The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs' dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy efficient initiatives across its operations, and active engagement with its value chain partners.

Powered by Capital Market - Live News

Revenue from operations grew 19.9% to Rs 537.78 crore in the quarter ended 31 December 2024.

Profit before tax was at Rs 100.63 crore in the third quarter of FY25, up 36.3% from Rs 73.82 crore posted in the same period a year ago.

Total expenses increased 17.5% to Rs 442.18 crore in Q3 FY25, compared to Rs 376.26 crore reported in Q3 FY24. The cost of material consumed stood at Rs 261.19 crore (up 21.5% YoY), employee benefit expenses was at Rs 41.63 crore (up 15.1% YoY) and finance costs stood at Rs 9.97 crore (up 122.5% YoY) during the period under review.

On nine-month basis, the company's consolidated net profit jumped 21.4% to Rs 184.06 crore in 9M FY25, compared to Rs 151.65 crore in 9M FY24. Revenue from operations rose 15.2% YoY to Rs 1,551.30 crore in 9M FY25.

The company's board has declared an interim dividend of Rs 2.5 per equity share for the financial year 2024-25. The record date for the payment of the interim dividend has been set for Friday, 14 February 2025.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India.

Powered by Capital Market - Live News

Net profit of Aarti Pharmalabs rose 40.24% to Rs 73.99 crore in the quarter ended December 2024 as against Rs 52.76 crore during the previous quarter ended December 2023. Sales rose 19.86% to Rs 537.78 crore in the quarter ended December 2024 as against Rs 448.69 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News